Assessment of colour vision in epileptic patients exposed to single-drug therapy

Diplopia, blurred vision and colour disturbances are well-known side effects associated with anti-epileptic drugs (AEDs). Farnsworth-Munsell 100-hue colour test (F-100) is an accepted and sensitive tool to detect changes in colour perception. To determine the impact of AEDs upon colour vision, we ev...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autor principal: López, L.
Otros Autores: Thomson, A., Rabinowicz, A.L
Formato: Capítulo de libro
Lenguaje:Inglés
Publicado: 1999
Acceso en línea:Registro en Scopus
DOI
Handle
Registro en la Biblioteca Digital
Aporte de:Registro referencial: Solicitar el recurso aquí
LEADER 06765caa a22009857a 4500
001 PAPER-19555
003 AR-BaUEN
005 20230518205054.0
008 190411s1999 xx ||||fo|||| 00| 0 eng|d
024 7 |2 scopus  |a 2-s2.0-0345211602 
024 7 |2 cas  |a Anticonvulsants; Carbamazepine, 298-46-4; Phenytoin, 57-41-0; Valproic Acid, 99-66-1 
040 |a Scopus  |b spa  |c AR-BaUEN  |d AR-BaUEN 
030 |a EUNEA 
100 1 |a López, L. 
245 1 0 |a Assessment of colour vision in epileptic patients exposed to single-drug therapy 
260 |c 1999 
270 1 0 |m Lopez, L.; Seccion Neura-oftalmologia, Inst. Invest. Neurol. Raul Carrea, FLENI, Montaneses 2325, 1428 Buenos Aires, Argentina; email: llopez@roche.com.ar 
506 |2 openaire  |e Política editorial 
504 |a Dichter, M., Brodie, M., New antiepileptic drugs (1996) N Engl J Med, 334, pp. 1583-1590 
504 |a Mattson, R., Cramer, J., Collins, J., Comparison of carbamazepine, phenobarbital, phenytoin and primidone in partial and secondarily generalized tonic-clonic seizures (1985) N Engl J Med, 313, pp. 145-151 
504 |a Macdonald, R.L., Kelly, K.M., Mechanism of action of currently prescribed and newly developed antiepileptic drugs (1994) Epilepsia, 35 (SUPPL. 4), pp. S41-S50 
504 |a Schmidt, D., (1982) Adverse Effects of Antiepileptic Drugs, pp. 125-127. , New York, Raven Press 
504 |a Verriest, G., Van Laethem, J., Uvijls, A., A new assessment of the normal ranges of the Farnsworth-Munsell 100-hue test scores (1982) Am J Ophthalmol, 93, pp. 635-642 
504 |a Smith, V.C., Pokorny, J., Pass, A., Color-axis determination on the Farnsworth-Munsell 100-hue test (1985) Am J Ophthalmol, 100, pp. 176-182 
504 |a Büttner, Th., Patzld, T., Kuhn, W., Muller, Th., Przuntek, H., Impairment of colour discrimination in Parkinson's disease (1994) Neuroophthalmology, 4, pp. 91-95 
504 |a Haug, B.A., Kolle, R.U., Trenkwalder, C., Oertel, W.H., Paulus, W., Predominant affection of the blue-cone pathway in Parkinson's disease (1995) Brain, 118, pp. 771-778 
504 |a Hart W.M., Jr., Acquired dyschromatopsia (1987) Surv Ophthalmol, 32, pp. 10-31 
504 |a Paulus, W., Schwarz, G., Steinhoff, B., The effect of anti-epileptic drugs on visual perception in patients with epilepsy (1996) Brain, 119, pp. 539-549 
504 |a Bayer, A.U., Thiel, J., Zrenner, E., Dichgans, J., Kuehn, M., Paulus, W., Ried, S., Schmidt, D., Color vision test for early detection of antiepileptic drug toxicity (1997) Neurology, 48, pp. 1394-1397 
504 |a Hood, D.C., Benimoff, N.L., Greenstein, V.C., The response range of the blue-cone pathways: A source of vulnerability disease (1984) Invest Ophthalmol Vis Sci, pp. 864-867 
504 |a Falk, G., Retinal physiology (1991) Principles and Practice of Electrophysiology of Vision, pp. 69-84. , Heckenlively JR, Arden GB (eds): St Louis, Mosby 
504 |a Wäsle, H., Boycott, B.B., Functional architecture of the mammalian retina (1991) Physiol Rev, 71, pp. 447-480 
504 |a Kolb, H., The neural organization in human retina (1991) Principles and Practice of Clinical Electrophysiology of Vision, pp. 25-52. , Heckenlively JR, Arden GB (eds): St Louis, Mosby 
520 3 |a Diplopia, blurred vision and colour disturbances are well-known side effects associated with anti-epileptic drugs (AEDs). Farnsworth-Munsell 100-hue colour test (F-100) is an accepted and sensitive tool to detect changes in colour perception. To determine the impact of AEDs upon colour vision, we evaluated 37 consecutive patients with complex partial seizures exposed to monotherapy with phenytoin (PHT, carbamazepine (CBZ) or valproic acid (VPA). All had normal IQ and no congenital disturbances in colour vision or ocular diseases. Twenty normal controls were used for statistical analysis. Thirteen patients were exposed to PHT, 12 to CBZ and 12 to VPA. Visual colour perception was impaired in 30/37 (82%) of the study group. The most significant abnormality was detected in the blue-yellow axis in 10/13 patients exposed to PHT (p < 0.02) and in 8/12 treated with CBZ (p < 0.009). In 8/12 patients taking VPA, no significant abnormality was observed (p < 0.06). None of the studied patients complained of colour vision disturbances. Our findings strongly support the negative effect of AEDs upon colour vision discrimination, most likely due to changes at the retinal processing level. F-100 proved to be very useful to assess early toxicity due to AEDs.  |l eng 
593 |a Neurology Department, Raul Carrea Inst. for Neurol. Res., Buenos Aires, Argentina 
593 |a Neurology Service, British Hospital, Buenos Aires, Argentina 
593 |a Secc. Neuro-oftalmología, Inst. Invest. Neurologicas Raul C., Montañeses 2325, 1428 Buenos Aires, Argentina 
690 1 0 |a COLOUR DISCRIMINATION 
690 1 0 |a EPILEPTIC PATIENTS 
690 1 0 |a FARNSWORTH-MUNSELL 100-HUE TEST 
690 1 0 |a ANTICONVULSIVE AGENT 
690 1 0 |a CARBAMAZEPINE 
690 1 0 |a PHENYTOIN 
690 1 0 |a VALPROIC ACID 
690 1 0 |a ADOLESCENT 
690 1 0 |a ADULT 
690 1 0 |a AGED 
690 1 0 |a ARTICLE 
690 1 0 |a CLINICAL ARTICLE 
690 1 0 |a COLOR VISION DEFECT 
690 1 0 |a CONTROLLED STUDY 
690 1 0 |a EPILEPSY 
690 1 0 |a FEMALE 
690 1 0 |a FILTER 
690 1 0 |a HUMAN 
690 1 0 |a MALE 
690 1 0 |a PRIORITY JOURNAL 
690 1 0 |a VISION TEST 
690 1 0 |a ADOLESCENT 
690 1 0 |a ADULT 
690 1 0 |a AGED 
690 1 0 |a ANTICONVULSANTS 
690 1 0 |a CARBAMAZEPINE 
690 1 0 |a COLOR PERCEPTION 
690 1 0 |a COLOR VISION DEFECTS 
690 1 0 |a DIPLOPIA 
690 1 0 |a EPILEPSY, COMPLEX PARTIAL 
690 1 0 |a FEMALE 
690 1 0 |a HUMANS 
690 1 0 |a MALE 
690 1 0 |a MIDDLE AGED 
690 1 0 |a PHENYTOIN 
690 1 0 |a SEVERITY OF ILLNESS INDEX 
690 1 0 |a SINGLE-BLIND METHOD 
690 1 0 |a VALPROIC ACID 
700 1 |a Thomson, A. 
700 1 |a Rabinowicz, A.L. 
773 0 |d 1999  |g v. 41  |h pp. 201-205  |k n. 4  |p Eur. Neurol.  |x 00143022  |w (AR-BaUEN)CENRE-4689  |t European Neurology 
856 4 1 |u https://www.scopus.com/inward/record.uri?eid=2-s2.0-0345211602&doi=10.1159%2f000008051&partnerID=40&md5=0e72fd077540c4bc53a188b0ba5b34d5  |y Registro en Scopus 
856 4 0 |u https://doi.org/10.1159/000008051  |y DOI 
856 4 0 |u https://hdl.handle.net/20.500.12110/paper_00143022_v41_n4_p201_Lopez  |y Handle 
856 4 0 |u https://bibliotecadigital.exactas.uba.ar/collection/paper/document/paper_00143022_v41_n4_p201_Lopez  |y Registro en la Biblioteca Digital 
961 |a paper_00143022_v41_n4_p201_Lopez  |b paper  |c PE 
962 |a info:eu-repo/semantics/article  |a info:ar-repo/semantics/artículo  |b info:eu-repo/semantics/publishedVersion 
999 |c 80508